Permanent repeal of the so-called Cadillac tax on “high-cost” employer-sponsored health coverage will happen within days as part of a year-end government spending package slated for enactment. Other Affordable Care Act (ACA) changes in the package include repeal of the taxes on health insurers and medical devices, as well as extension of the annual employer fee for the Patient-Centered Outcomes Research Institute (PCORI). The deal also extends the tax credit for employer-paid family and medical leave. Congress is expected to clear the spending deal for the president’s signature before government funding expires at midnight Friday.
Repeal of the Cadillac tax caps off years of efforts by a broad range of stakeholders, including Mercer and the Alliance to Fight the 40, a coalition organized by the American Benefits Council. Those efforts aimed to educate lawmakers about the adverse consequences of the tax and the value of employer-provided healthcare coverage. Congress has twice delayed the tax, and in July, the House overwhelmingly approved a stand-alone bill (HR 748) to repeal the tax. Senate counterpart legislation (S 684) had more than 60 cosponsors, and more than 1,000 employers — including Mercer and many of its clients — signed on to a Dec. 5 letter urging the Senate to act.
By axing the ACA’s Cadillac, health insurance (repealed effective 2021) and medical device (repealed effective 2020) taxes, the spending package removes nearly all of the law’s major funding provisions, except the employer shared-responsibility assessments. The Congressional Budget Office (CBO) projects repeal of the Cadillac tax will cost nearly $200 billion over 10 years. Earlier estimates from the CBO said repeal of the medical device tax would cost about $24 billion over a decade, while the IRS estimated earlier this year that repeal of the health insurance tax would amount to revenue losses of $15.5 billion just in 2020.
Other provisions of interest to employers and health insurers in the spending legislation include:
The package does not include broader drug-pricing reforms or legislation to stop surprise out-of-network medical bills, although efforts to enact those measures will continue next year.